var data={"title":"Cytomegalovirus immune globulin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cytomegalovirus immune globulin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5969?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cytomegalovirus-immune-globulin-drug-information\" class=\"drug drug_general\">see &quot;Cytomegalovirus immune globulin: Drug information&quot;</a> and <a href=\"topic.htm?path=cytomegalovirus-immune-globulin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cytomegalovirus immune globulin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156155\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>CytoGam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4663230\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>CytoGam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046791\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Immune Globulin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046785\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cytomegalovirus-immune-globulin-drug-information\" class=\"drug drug_general\">see &quot;Cytomegalovirus immune globulin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: <b>Note:</b> Refer to individual protocols.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Prophylaxis of CMV disease in kidney transplant: </b>Initial: IV: 150 mg/kg within 72 hours of transplant; 100 mg/kg at weeks 2, 4, 6, and 8 after transplant and 50 mg/kg at weeks 12 and 16 after transplant</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Prophylaxis of CMV disease in liver, lung, pancreas, or heart transplant (CMV (+) donor and CMV (-) recipient):</b> IV: 150 mg/kg within 72 hours of transplant, 150 mg/kg at weeks 2, 4, 6, and 8 after transplant; 100 mg/kg at weeks 12 and 16 after transplant </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Treatment, CMV disease:</b> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Ganciclovir-resistant infection and disease: IV: 100 mg/kg/dose weekly in combination with other antivirals (eg, ganciclovir, foscarnet, cidofovir); duration of therapy dependent upon CMV antigenemia assay (pp65) or PCR (Bueno, 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pneumonitis, severe: Children and Adolescents: IV: 400 mg/kg on days 1, 2, and 7 followed by 200 mg/kg on days 14; if still symptomatic, may administer an additional 200 mg/kg on day 21; use in combination with ganciclovir (Reed, 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Prophylaxis of CMV disease in kidney transplant:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Initial dose (within 72 hours of transplant): 150 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">2-, 4-, 6-, and 8 weeks after transplant: 100 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">12 and 16 weeks after transplant: 50 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Prophylaxis of CMV disease in liver, lung, pancreas, or heart transplant:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Initial dose (within 72 hours of transplant): 150 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">2-, 4-, 6-, and 8 weeks after transplant: 150 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">12 and 16 weeks after transplant: 100 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage adjustment in renal impairment:</b> No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution. Infuse at minimum rate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156142\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CytoGam&reg;: 50 mg (&plusmn; 10 mg)/mL (50 mL) [contains sodium 20-30 mEq/L, human albumin, and sucrose 50 mg/mL]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156128\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046794\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV infusion: Does not require further dilution; administer as a 50 mg/mL solution through a dedicated IV line containing an in-line 15 micron filter (a 0.2 micron filter is also acceptable) using an infusion pump. Do not mix with other infusions; do not use if turbid. Begin infusion within 6 hours of entering vial, complete infusion within 12 hours of vial entry. Infusion with other products is not recommended; however, if unavoidable, may be piggybacked into an IV line of  NS, D<sub>5</sub>W, D<sub>10</sub>W, or dextrose 20% in water. Do not dilute more than 1:2.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Initial infusion: Begin at 15 mg/kg/hour; if there are no infusion-related reactions after 30 minutes, increase to 30 mg/kg/hour; if no infusion-related reactions after 30 minutes, increase to 60 mg/kg/hour for the remainder of the infusion; infusion rate should not exceed 75 mL/hour. Monitor closely after each rate change. If patient develops nausea, back pain, or flushing during infusion, slow the rate or temporarily stop the infusion. Discontinue if blood pressure drops or in case of anaphylactic reaction.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Subsequent infusions: Initiate at 15 mg/kg/hour for the first 15 minutes, if no infusion-related reactions, increase to 30 mg/kg/hour for the next 15 minutes; if rate is tolerated, increase to 60 mg/kg/hour and maintain this rate until completion of dose; maximum infusion rate: 60 mg/kg/hour or not to exceed 75 mL/hour.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156151\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store refrigerated between 2&deg;C and 8&deg;C (36&deg;F and 46&deg;F). Infusion should begin within 6 hours after entering the vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046793\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prophylaxis of cytomegalovirus (CMV) disease associated with kidney, lung, liver, pancreas, or heart transplantation [FDA approved in pediatric patients (age not specified) and adults]; concomitant use with ganciclovir should be considered in organ transplants other than kidney from CMV seropositive donors to CMV seronegative recipients; has also been used for CMV treatment in hematopoietic stem cell transplantation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156182\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">CytoGam may be confused with Cytoxan, Gamimune N</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156179\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Chills </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, muscle cramps</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abdominal pain, acute renal failure, acute respiratory distress, anaphylactic shock, angioedema, anuria, apnea, aseptic meningitis, bronchospasm, bullous dermatitis, circulatory shock, coma, cyanosis, decreased blood pressure, dyspnea, epidermolysis, erythema multiforme, hemolysis, hepatic insufficiency, hypersensitivity reaction (systemic), hypotension, hypoxemia, increased blood urea nitrogen, increased serum creatinine, leukopenia, loss of consciousness, oliguria, osmotic nephrosis, pancytopenia, positive direct Coombs test, proximal tubular nephropathy, pulmonary edema, renal insufficiency, renal tubular necrosis, rigors, seizure, Stevens-Johnson syndrome, thromboembolism, transfusion-related acute lung injury, tremor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156147\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cytomegalovirus immune globulin (CMV-IGIV), other immunoglobulin preparations, or any component of the formulation; selective immunoglobulin A deficiency </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156132\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; monitor vital signs during infusion; discontinue immediately for hypotension or anaphylaxis; immediate treatment (including epinephrine 1 mg/mL) should be available. Systemic allergic reactions are rare; may be treated with epinephrine and diphenhydramine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with intravenous immune globulin administration (rare); may occur with high doses (&ge;2 g/kg). Symptoms include severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements and nausea and vomiting. Syndrome usually appears within several hours to 2 days following treatment; usually resolves within several days after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemolysis: Intravenous immune globulin has been associated with antiglobulin hemolysis; monitor for signs of hemolytic anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary edema: Monitor for adverse pulmonary events including transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with intravenous immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function and  usually occurs within 1-6 hours after infusion; may be managed with oxygen and respiratory support. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment:  Acute renal dysfunction (increased serum creatinine, oliguria, osmotic nephrosis, acute renal failure) can rarely occur; usually within 7 days of use (more likely with products stabilized with sucrose). Patients at risk for renal failure include the elderly, patients with preexisting renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications. In patients at risk of renal dysfunction, the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombotic events: Thrombotic events have been reported with administration of intravenous immune globulin; patients at risk include those with advanced age or a history of atherosclerosis, cardiovascular and/or thrombotic risk factors, or known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypovolemia: Patients should not be volume depleted prior to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in patients &gt;65 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Albumin: Product is stabilized with albumin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sucrose: Product is stabilized with sucrose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299116\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156136\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12926&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<b> Exceptions: </b>Influenza Virus Vaccine (Live/Attenuated); Rotavirus Vaccine; Yellow Fever Vaccine; Zoster Vaccine (Live/Attenuated).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156138\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156149\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046790\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function (BUN, serum creatinine prior to initial infusion and periodically thereafter); urine output; vital signs, including blood pressure (throughout infusion); signs/symptoms of infusion-related adverse reactions, anaphylaxis; signs and symptoms of hemolytic anemia; blood viscosity (baseline; in patients at risk for hyperviscosity); presence of antineutrophil antibodies (if TRALI is suspected); volume status; weight gain; clinical response</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156131\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">CMV-IGIV is a preparation of immunoglobulin G (and trace amounts of IgA and IgM) derived from pooled healthy blood donors and contains a high titer of CMV antibodies; administration provides a passive source of antibodies against cytomegalovirus to attenuate or reduce the incidence of serious CMV disease </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45755632\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">Half-life elimination: 8 to 24 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046798\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IgA content: Trace </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Plasma Source: 2000-5000 donors (5% with top CMV titers) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IgG subclass (%): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IgG<sub>1</sub>: 65 </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IgG<sub>2</sub>: 28 </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IgG<sub>3</sub>: 5.2 </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IgG<sub>4</sub>: 1.7 </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Monomers + dimer (%): &ge;95 monomers + dimers </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gamma globulin (%): 99 </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Albumin: 10 mg/mL </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Sodium content: 20-30 mEq/L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Sugar content: 5% sucrose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Osmolality: &gt;200 mOsm/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323090\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Injection</b> (Cytogam Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (50 mL): $1,542.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3462463\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cytotec (BB);</li>\n      <li>Megalotect (IL, KR, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bowden RA, Fisher LD, Rogers K, et al, &ldquo;Cytomegalovirus (CMV)-Specific Intravenous Immunoglobulin for the Prevention of Primary CMV Infection and Disease After Marrow Transplant,&rdquo; <i>J Infect Dis</i>, 1991, 164(3):483-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/1651360/pubmed\" target=\"_blank\" id=\"1651360\">1651360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bueno J, Ramil C, and Green M, &quot;Current Management Strategies for the Prevention and Treatment of Cytomegalovirus Infection in Pediatric Transplant Recipients,&quot; <i>Paediatr Drugs</i>, 2002, 4(5):279-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/11994033/pubmed\" target=\"_blank\" id=\"11994033\">11994033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reed EC, Bowden RA, Dandliker PS, et al, &quot;Treatment of Cytomegalovirus Pneumonia With Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients With Bone Marrow Transplants,&quot; Ann Intern Med, 1988, 109(10):783-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/2847610/pubmed\" target=\"_blank\" id=\"2847610\">2847610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Snydman DR, Werner BG, Dougherty NN, et al, &ldquo;Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation. A Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo; <i>Ann Intern Med</i>, 1993, 119(10):984-91. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/8214995 /pubmed\" target=\"_blank\" id=\"8214995 \">8214995 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valantine HA, Luikart H, Doyle R, et al, &ldquo;Impact of Cytomegalovirus Hyperimmune Globulin on Outcome After Cardiothoracic Transplantation: A Comparative Study of Combined Prophylaxis With CMV Hyperimmune Globulin Plus Ganciclovir Versus Ganciclovir Alone,&rdquo; <i>Transplantation</i>, 2001, 72(10):1647-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cytomegalovirus-immune-globulin-pediatric-drug-information/abstract-text/11726825/pubmed\" target=\"_blank\" id=\"11726825\">11726825</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12926 Version 85.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F156155\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F4663230\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046791\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046785\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F156142\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F156128\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046794\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F156151\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046793\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F156182\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156179\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156147\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156132\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299116\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156136\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F156138\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F156149\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046790\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156131\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F45755632\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1046798\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323090\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F3462463\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12926|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cytomegalovirus-immune-globulin-drug-information\" class=\"drug drug_general\">Cytomegalovirus immune globulin: Drug information</a></li><li><a href=\"topic.htm?path=cytomegalovirus-immune-globulin-patient-drug-information\" class=\"drug drug_patient\">Cytomegalovirus immune globulin: Patient drug information</a></li></ul></div></div>","javascript":null}